Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

fluoxetine

Adjunctive therapy

Brand: PROZAC

Published 2026-01-25 · Last reviewed 2026-02-01 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Typical adult start is 20 mg once daily (often morning); may increase to 40–60 mg/day after several weeks if needed and tolerated.·Half-life: Tmax 6–8 h; half-life 4–6 days at steady state; active metabolite norfluoxetine half-life 7–15 days.·LAI available: No

Class: Adjunctive therapy
Typical dose: Typical adult start is 20 mg once daily (often morning); may increase to 40–60 mg/day after several weeks if needed and tolerated.
Half-life: Tmax 6–8 h; half-life 4–6 days at steady state; active metabolite norfluoxetine half-life 7–15 days.
LAI available: No

Quick answers

What is fluoxetine?: Fluoxetine (Prozac) is a long half-life SSRI used for depression, OCD, bulimia nervosa, and bipolar depression (in combination with olanzapine).
What is PROZAC?: PROZAC is a brand name for fluoxetine.
What is PROZAC (fluoxetine) used for?: Label indications include: Major depressive disorder; OCD; panic disorder; use with olanzapine for bipolar depression.
What drug class is PROZAC (fluoxetine)?: SSRI Antidepressant.
What is the mechanism of action of PROZAC (fluoxetine)?: Selective serotonin reuptake inhibitor (SSRI).
What strengths does PROZAC (fluoxetine) come in?: Capsules 10–40 mg, tablets 10–60 mg, delayed-release capsule 90 mg weekly, oral solution 20 mg/5 mL.

General information

Fluoxetine (Prozac) is a long half-life SSRI used for depression, OCD, bulimia nervosa, and bipolar depression (in combination with olanzapine).

Because norfluoxetine persists for weeks, side effects and interaction risk can outlast the last dose; switching plans often require longer washouts than other SSRIs.

The compare view and fluoxetine evidence feed can help weigh activation, discontinuation, and interaction trade-offs when revising maintenance plans.

Its activating profile and low discontinuation risk make it useful in adherence-challenged patients. In patients with bipolar-spectrum risk, mania/hypomania screening and mood-stabiliser coordination are common; the bipolar disorder hub and fluoxetine print page can support shared decision-making.

U.S. approvals

Major depressive disorder (1987)
Obsessive-compulsive disorder (1994)
Bulimia nervosa (1994)

Formulations & strengths

Capsules 10–40 mg, tablets 10–60 mg, delayed-release capsule 90 mg weekly, oral solution 20 mg/5 mL.

Generic availability

Generic formulations widely available.

Potent CYP2D6 inhibition can require dose adjustments for many psychotropics (e.g., risperidone, aripiprazole, TCAs).

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Selective serotonin reuptake inhibitor with mild 5-HT2C antagonism that may contribute to activation.

SERT inhibitor with minimal other receptor affinity.

Metabolism & pharmacokinetics

Tmax 6–8 h; half-life 4–6 days at steady state; active metabolite norfluoxetine half-life 7–15 days.
Metabolized by CYP2D6; eliminated renally as metabolites.
Hepatic impairment can prolong exposure; dose reductions or alternate-day dosing are sometimes used when tolerability limits continuation.
Long half-life means steady state takes weeks and missed doses have less immediate impact, but adverse effects may also take longer to resolve.

Dosing & administration

Typical adult start is 20 mg once daily (often morning); may increase to 40–60 mg/day after several weeks if needed and tolerated.
Lower initial doses (10 mg) are often used in anxiety disorders.
For panic-spectrum presentations where activation is a concern, gradual titration is often used to reduce early jitteriness and insomnia.
A 5-week washout is required before starting MAOI therapy due to long half-life.
Once-weekly delayed-release dosing is sometimes used after stabilization on daily therapy; suitability for comorbid hepatic disease is typically confirmed, and labeling is reviewed for transition timing.

Monitoring & labs

Suicidality and psychiatric activation (anxiety, agitation, mood elevation) during initiation and dose changes, especially in younger patients.
Sodium in older adults or patients on diuretics if symptoms suggest hyponatremia (confusion, fatigue, gait change).
Bleeding/bruising risk when combined with NSAIDs, antiplatelets, or anticoagulants; early symptom reporting is often reinforced.
Medication reconciliation to avoid serotonergic combinations and to anticipate prolonged interaction windows after stopping.

Fluoxetine’s long half-life lowers discontinuation risk but prolongs both adverse effects and interaction risk after the last dose.

Adverse effects

FDA boxed warnings

Antidepressants increase suicidality risk in young adults; closer monitoring is common.

Common side effects (≥10%)

Insomnia/activation: Morning dosing is often considered.
Nausea: Often improves after several days.
Diarrhea: Dietary adjustments can help.
Sexual dysfunction: Management strategies can be discussed.

Other notable effects

Hyponatremia (SIADH) risk; sodium monitoring is common in older adults and other higher-risk patients.
Weight change (initial weight loss possible).
Activation, anxiety, or mania symptoms can emerge in susceptible patients; closer monitoring is common when treating bipolar-spectrum depression.
Bleeding risk can increase when combined with NSAIDs, antiplatelets, or anticoagulants; counseling often covers bruising and GI bleeding symptoms.
Serotonin syndrome is uncommon on monotherapy but becomes more likely with serotonergic combinations; counseling often covers escalation guidance for agitation, tremor, clonus, and fever.

Interactions

Potent CYP2D6 inhibitor—coadministered CYP2D6 substrates (TCAs, antipsychotics, beta-blockers) may require dose adjustment and monitoring.
Contraindicated with MAOIs; a 5-week washout after stopping fluoxetine is required before initiating an MAOI.
Reduces tamoxifen efficacy due to CYP2D6 inhibition.
Caution is common with other serotonergic agents (triptans, tramadol, linezolid) that can raise serotonin syndrome risk; interaction risk can persist for weeks after stopping due to long half-life.
Other strong CYP2D6 substrates with narrow therapeutic windows (e.g., TCAs) may require dose adjustment and clinical monitoring when combined.

Other useful information

Long half-life reduces discontinuation risk but prolongs adverse effects after stopping.
Metabolic parameters are commonly assessed when combined with olanzapine (Symbyax).
When switching therapies (especially to or from MAOIs), washout periods are planned deliberately and a safety-monitoring plan is commonly documented rather than rapid cross-tapers.
When paired with olanzapine (Symbyax), metabolic monitoring follows the antipsychotic component; baseline weight, lipids, and glucose are typically documented and rechecked during early months.

References

Related hubs:SMI toolkit·Support resources